FDA DEVICE FACTS
Arctic Front Advance and Arctic Front Advance Pro Cryoablation Catheter
Medtronic Cryocath, LP
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
The Arctic Front Advance and Arctic Front Advance Pro Cardiac Cryoablation Catheter is indicated for the treatment of recurrent symptomatic paroxysmal atrial fibrillation and the treatment of drug refractory recurrent symptomatic persistent atrial fibrillation (episode duration less than 6 months). The Arctic Front Advance and Arctic Front Advance Pro Cardiac Cryoablation Catheters are also indicated for the treatment of recurrent symptomatic paroxysmal atrial
fibrillation as an alternative to antiarrhythmic drug therapy as an initial rhythm control strategy. The Freezor MAX Cardiac Cryoablation Catheter is used as an adjunctive device in the endocardial treatment of paroxysmal and persistent atrial fibrillation (episode duration less than 6 months) in conjunction with the Arctic Front Cryocatheter for the following uses:
• Gap cryoablation to complete electrical isolation of the pulmonary veins
• Cryoablation of focal trigger sites
• Creation of ablation line between the inferior vena cava and the tricuspid valve
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。